Press releases
Browse GSK global press releases issued since 2009. Search them by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
New Phase IIIb/IV data show switching to once-daily Triumeq® maintains HIV viral suppression
ViiV Healthcare today announced 24-week data from the Phase IIIb/IV STRIIVING study
-
GSK starts build of its largest Indian tablet manufacturing pharmaceutical factory in Vemgal, Karnataka
Hon’ble Chief Minister of Karnataka, Shri Siddaramaiah lays the foundation stone of the new pharmaceutical factory
-
GSK and Theravance announce results from the SUMMIT COPD CV Survival Study
GSK and THRX announced initial results from study for Relvar®Breo® Ellipta® 100/25mcg (fluticasone furoate ‘FF’/vilanterol ‘VI’ or ‘FF/VI’).
-
GSK announces NEJM publication of Phase 3b/4 study of ambrisentan and tadalafil as first-line combination treatment in patients with pulmonary arterial hypertension
GSK today announced publication of first-line combination therapy of ambrisentan and tadalafil in treatment-naïve patients with PAH.
-
GSK to divest ofatumumab for auto-immune indications to Novartis for up to $1 billion plus royalties
GSK announced an agreement with Novartis Pharma to divest its rights in ofatumumab for auto-immune indications, incl. multiple sclerosis.
-
Results Announcement for the second quarter 2015
GSK delivers Q2 Group sales of £5.9 billion +7% CER and core EPS of 17.3p (flat CER) in first full quarter of performance since transaction
-
GSK’s Synflorix™ receives CHMP positive opinion for major label extension
GSK announced that the CHMP of EMA has issued a positive opinion for the expansion of the SynflorixTM European label
-
GSK’s malaria candidate vaccine, Mosquirix™ (RTS,S), receives positive opinion from European regulators for the prevention of malaria in young children in sub-Saharan Africa
GSK announced that the CHMP of EMA has adopted a positive scientific opinion for its malaria candidate vaccine Mosquirix.
-
GSK and Save the Children launch 2015 call for developing country healthcare innovations to reduce child deaths
GSK and Save the Children announce the launch of their third annual $1 million Healthcare Innovation Award.
-
GSK and the Francis Crick Institute join forces in collaboration to forge new scientific discoveries
The Francis Crick Institute and GSK to partner on an innovation collaboration exploring new avenues of medical research and drug discovery
-
Regulatory update on divestment of Nimenrix and Mencevax
GSK is divesting its meningitis vaccines Nimenrix and Mencevax to Pfizer Ireland Pharmaceuticals (a subsidiary of Pfizer Inc).
-
GSK to create independent research institute with goal of radically changing and improving medicines development
Seattle-based Altius Institute for Biomedical Sciences to pioneer new understanding of cell “operating systems”
-
GSK announces outcome of US FDA Advisory Committee recommending approval of mepolizumab for the treatment of adults with severe asthma
GSK announced outcome regarding the BLA for mepolizumab as an add-on maintenance treatment for severe asthma with eosinophilic inflammation.
-
GSK submits Japan regulatory application for mepolizumab in severe eosinophilic asthma
GSK announced application to the Japanese MHLW for mepolizumab as add-on maintenance treatment for patients with severe eosinophilic asthma
-
GSK to support training of frontline health workers across Ghana, Kenya and Nigeria
GSK is to support the training of more than 9,000 health workers in Ghana, Kenya and Nigeria over the next three years.
-
GSK presents data at ATS on the role of blood eosinophil levels as a potential biomarker in the treatment of COPD
GSK presented data on the role of blood eosinophils as a potential biomarker to determine responsiveness to treatment with ICS
-
GSK’s ECLIPSE study shows association between improving health status and reduced morbidity and mortality in patients with COPD
keeping stable health status in patients with COPD significantly reduces the likelihood of exacerbation, hospital admission and dying.
-
GSK responds to latest report from the O’Neill Review on antibiotic resistance
It is essential that we find new ways to increase antibiotics R&D and create a future pipeline of new treatments.
-
GSK and UNC-Chapel Hill announce novel partnership to accelerate search for HIV cure
Unique collaboration will create HIV Cure center and a new company to bring together academic and pharmaceutical research scientists
-
GlaxoSmithKline plc announces Board and Committee changes
GSK today announces that Manvinder Singh (Vindi) Banga will join GSK’s Board as a Non-Executive Director on 1 September 2015.